- Management will hold a conference call on
Thursday, November 2 at 4:30 p.m. ET/1:30 p.m.
PT -
SAN
DIEGO, Oct. 26, 2023 /PRNewswire/ -- Cardiff
Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology
company leveraging PLK1 inhibition to develop novel therapies
across a range of cancers, today announced that it plans to release
financial results for the third quarter ended September 30, 2023 on Thursday, November 2 after the close of
trading.
Conference Call and Webcast
Cardiff Oncology will host a conference call and live webcast
at 4:30 p.m. ET/1:30 p.m. PT on November, 2 2023.
Individuals interested in listening to the live conference call may
do so by using the webcast link in the "Investors" section of the
company's website at
https://cardiffoncology.investorroom.com/events. A replay will be
available in the investor relations section on the company's
website following the completion of the call.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company
leveraging PLK1 inhibition, a well-validated oncology drug target,
to develop novel therapies across a range of cancers. The Company's
lead asset is onvansertib, a PLK1 inhibitor being evaluated in
combination with standard-of-care (SoC) therapeutics in clinical
programs targeting indications such as RAS-mutated metastatic
colorectal cancer (mCRC) and metastatic pancreatic ductal
adenocarcinoma (mPDAC), as well as in investigator-initiated trials
in small cell lung cancer (SCLC) and triple negative breast cancer
(TNBC). These programs and the Company's broader development
strategy are designed to target tumor vulnerabilities in order to
overcome treatment resistance and deliver superior clinical benefit
compared to the SoC alone. For more information, please visit
https://www.cardiffoncology.com.
Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com
Investor Contact:
Kiki
Patel, PharmD
Gilmartin Group
332-895-3225
Kiki@gilmartinir.com
Media Contact:
Richa
Kumari
Taft Communications
551-344-5592
richa@taftcommunications.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-to-report-third-quarter-2023-financial-results-and-provide-business-update-301969276.html
SOURCE Cardiff Oncology, Inc.
